Why the study?
Does telmisartan reduce the lipopolysaccharide-induced innate immune response in human monocytes?
Population
Human circulating monocytes and monocytic THP-1 (human acute monocytic leukemia cell line) cells
Comparison
Telmisartan pre-incubation before exposure to 50… vs Exposure to 50 ng/ml lipopolysaccharide without…
Design
Preclinical
Authors
Loading...
May attenuate monocyte inflammation via PPARγ; leaves open clinical cardiovascular benefits.
Does telmisartan reduce the lipopolysaccharide-induced innate immune response in human monocytes?
Telmisartan exerts anti-inflammatory effects in human monocytes exposed to LPS primarily through PPARγ activation, suggesting potential pleiotropic benefits in cardiovascular and metabolic disorders.
Pang et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: